Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Shitara, K.; ÖZGÜROĞLU, Mustafa; Bang, Y-J; Di Bartolomeo, M.; Mandala, M.; Ryu, M-H; Caglevic, C.; Chung, H.; Muro, K.; Van Cutsem, E.; Kobie, J.; Cristescu, R.; Aurora-Garg, D.; Lu, J.; Shih, C-S; Adelberg, D.; Cao, Z.; Fuchs, C.

doi:10.1016/j.annonc.2021.05.803

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Atıf İçin Kopyala

Shitara K., ÖZGÜROĞLU M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.32, sa.9, ss.1127-1136, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 32 Sayı: 9
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.annonc.2021.05.803
Dergi Adı: ANNALS OF ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
Sayfa Sayıları: ss.1127-1136
Anahtar Kelimeler: pembrolizumab, chemotherapy, tumor mutational burden, gastroesophageal adenocarcinoma, gastric cancer, TUMOR MUTATIONAL BURDEN, CTLA-4 BLOCKADE, PD-1 BLOCKADE, BENEFIT, CHEMO
İstanbul Üniversitesi Adresli: Hayır

Özet

Background: In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with programmed death-ligand 1 (PD-L1) combined positive score (CPS) >= 1 tumors. The association of tissue tumor mutational burden (tTMB) status and clinical outcomes was determined, including the relationship with CPS and microsatellite instability-high (MSI-H) status.